Stay updated on STRO-002 Combo with Bevacizumab in Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the STRO-002 Combo with Bevacizumab in Ovarian Cancer Clinical Trial page.

Latest updates to the STRO-002 Combo with Bevacizumab in Ovarian Cancer Clinical Trial page
- Check4 days agoChange DetectedThe page's revision label updated from v3.3.3 to v3.3.4. No study details or content were modified. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check26 days agoChange DetectedIntroduced a new Locations section listing study sites in Florida, Pennsylvania, Tennessee, Virginia, and Wisconsin. The footer will show Revision: v3.3.3 and the HHS Vulnerability Disclosure link was removed.SummaryDifference0.6%

- Check55 days agoChange DetectedPublications are described as auto-filled from PubMed in the Publications section. The revision tag now shows version v3.3.2, replacing the previous v3.2.0 description.SummaryDifference0.1%

- Check62 days agoChange DetectedThe government funding/operating status notice was removed from the page. Core study details, eligibility criteria, and contacts remain unchanged.SummaryDifference0.4%

- Check77 days agoChange DetectedThe update appears to include non-substantive changes such as updated Study Record Dates and minor formatting; core study content (interventions, eligibility criteria, endpoints) remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check105 days agoChange DetectedCore content updated: adds a funding-lapse notice with open status for the NIH Clinical Center and directs to status sites; replaces version v3.1.0 with v3.2.0.SummaryDifference3%

Stay in the know with updates to STRO-002 Combo with Bevacizumab in Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the STRO-002 Combo with Bevacizumab in Ovarian Cancer Clinical Trial page.